Home › Companies › MAZE

Maze Therapeutics

Market cap $1.80B 54.7M shares (10-Q, Nov 4, 2026) × $32.87 close Nov 17, 2026

Most recent annual filing: 2026-03-25

Catalyst timeline

8 trackedQuarter catalyst calendar →
  1. Repinatrabit Otsuka Ph3 readoutLate 2026Repinatrabit Otsuka Ph3 readout, Late 2026, notable
  2. MAZE corporate updateNov 2026MAZE corporate update, Nov 2026, routine
  3. MZE829 readout1H 2027MZE829 readout, 1H 2027, major
  4. Inaxaplin Vertex interimEarly 2027Inaxaplin Vertex interim, Early 2027, major
  5. MZE782 Ph2 topline2027MZE782 Ph2 topline, 2027, material
  6. MZE829 pivotal start1H 2027MZE829 pivotal start, 1H 2027, notable
  7. MZE782 Ph2 start1H 2027MZE782 Ph2 start, 1H 2027, routine
  8. AZD2373 AstraZeneca Ph2b readoutOct 2027AZD2373 AstraZeneca Ph2b readout, Oct 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Technology platforms

Compass

Genetics-driven drug discovery platform that identifies and characterizes genetic variants associated with health and disease and determines how these drive risk for or protection against disease in specific patient groups through variant functionalization; purpose-built to inform all phases of drug discovery and development including clinical trial design; focus areas: kidney and metabolic diseases

Capital (as filed)

Cash
$154M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$236M Sep 30, 2026
Long-term investments
$87.3M Sep 30, 2026
Operating cash flow
−$32.8M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$477M cash, runway into 2029 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (2)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on Maze Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Maze Therapeutics (MAZE) - Scientific Deep Dive for MZE829, MZE782 and Pipeline Products APOL1 inhibition is validated but MZE829's broad-AMKD case rests on only four FSGS patients and eight others averaging -16.5%, while Vertex leads with more data, Breakthrough designation, and an accelerated-approval interim due before Maze's pivotal even starts; at ~$1.47B EV the market already prices a credible #2 with no margin of safety.
  2. Watch UPDATE: Maze Therapeutics (MAZE) - Fifty Patients and a Quiet ATM HORIZON enrollment to 50+ patients improves the quality of the coming binary readout but provides no new efficacy data; at ~$35 and ~$1.7B EV the stock has moved above the probability-weighted value with no new evidence, so the WATCH stance is maintained pending the non-FSGS cohort clearing ≥30% uACR with uPCR disclosed.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (18)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Nov 3, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

8 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)